Crestline Management, LP Esperion Therapeutics, Inc. Transaction History

Crestline Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $1.8 Million - $2.27 Million	-44,224 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $1.6 Million - $3.38 Million	44,224 New	44,224 $1.73 Million
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $1.15 Million - $1.78 Million	-26,350 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$43.8 - $52.77 $640,180 - $771,286	-14,616 Reduced 35.68%	26,350 $1.32 Million
Q2 2017 Aug 14, 2017	BUY	N/A	40,966	40,966 $1.9 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $171M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.